Publications by authors named "Caroline McCleary"
Nanoscale Mixed-Ligand Metal-Organic Framework for X-ray Stimulated Cancer Therapy.
J Am Chem Soc
December 2024
Concurrent localized radiotherapy and systemic chemotherapy are standards of care for many cancers, but these treatment regimens cause severe adverse effects in many patients. Herein, we report the design of a mixed-ligand nanoscale metal-organic framework (nMOF) with the ability to simultaneously enhance radiotherapeutic effects and trigger the release of a potent chemotherapeutic under X-ray irradiation. We synthesized a new functional quaterphenyl dicarboxylate ligand conjugated with SN38 (HQP-SN) via a hydroxyl radical-responsive covalent linkage.
View Article and Find Full Text PDFArticle Synopsis
- Heavy-metal-based nanoscale metal-organic frameworks (nMOFs) are proposed as effective radiosensitizers for radiotherapy by generating reactive oxygen species (ROS) that enhance energy deposition during treatment.
- A novel nMOF, Hf-TP-SN, has been designed with an X-ray-triggerable prodrug (SN38) for combined radiotherapy and chemotherapy, aiming to release drugs on-demand when exposed to X-ray irradiation.
- The results show that Hf-TP-SN significantly increases the release of SN38, leading to greater cytotoxicity against cancer cells and effectively inhibiting tumor growth in models of colon and breast cancer.
Monte Carlo Simulation-Guided Design of a Thorium-Based Metal-Organic Framework for Efficient Radiotherapy-Radiodynamic Therapy.
Angew Chem Int Ed Engl
November 2022
Article Synopsis
- High-Z metal-based nanoscale metal-organic frameworks (nMOFs) with photosensitizing ligands enhance radiation therapy effectiveness through a combined RT-RDT approach.
- Monte Carlo simulations indicate that Th-DBP nMOF outperforms Hf-DBP due to its superior mass attenuation coefficient, leading to greater radiation dose enhancement.
- In mouse models, low-dose X-ray treatment using Th-DBP significantly reduced tumor growth, achieving an 88% reduction in colon cancer and 97% in pancreatic cancer.